These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 16435211)

  • 41. Laronidase hypersensitivity and desensitization in type I mucopolysaccharidosis: a case report.
    Ensina LF; Aranda CS; de Lacerda AE; Camelo-Nunes I; Sole D; Martins AM; Castells M
    Pediatr Allergy Immunol; 2014 Aug; 25(5):498-9. PubMed ID: 25313426
    [No Abstract]   [Full Text] [Related]  

  • 42. Laronidase replacement therapy improves myocardial function in mucopolysaccharidosis I.
    Harada H; Uchiwa H; Nakamura M; Ohno S; Morita H; Katoh A; Yoshino M; Ikeda H
    Mol Genet Metab; 2011 Jul; 103(3):215-9. PubMed ID: 21482163
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Identification and molecular characterization of alpha-L-iduronidase mutations present in mucopolysaccharidosis type I patients undergoing enzyme replacement therapy.
    Yogalingam G; Guo XH; Muller VJ; Brooks DA; Clements PR; Kakkis ED; Hopwood JJ
    Hum Mutat; 2004 Sep; 24(3):199-207. PubMed ID: 15300847
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Intrathecal enzyme replacement therapy in a patient with mucopolysaccharidosis type I and symptomatic spinal cord compression.
    Munoz-Rojas MV; Vieira T; Costa R; Fagondes S; John A; Jardim LB; Vedolin LM; Raymundo M; Dickson PI; Kakkis E; Giugliani R
    Am J Med Genet A; 2008 Oct; 146A(19):2538-44. PubMed ID: 18792977
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Enzyme replacement therapy in feline mucopolysaccharidosis I.
    Kakkis ED; Schuchman E; He X; Wan Q; Kania S; Wiemelt S; Hasson CW; O'Malley T; Weil MA; Aguirre GA; Brown DE; Haskins ME
    Mol Genet Metab; 2001 Mar; 72(3):199-208. PubMed ID: 11243725
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Enzyme replacement therapy in 12 patients with MPS I-H/S with homozygous p.Leu490Pro mutation.
    Arora RS; Mercer J; Thornley M; Tylee K; Wraith JE
    J Inherit Metab Dis; 2007 Oct; 30(5):821. PubMed ID: 17570076
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Efficacy and safety of intravenous laronidase for mucopolysaccharidosis type I: A systematic review and meta-analysis.
    Dornelles AD; Artigalás O; da Silva AA; Ardila DLV; Alegra T; Pereira TV; Vairo FPE; Schwartz IVD
    PLoS One; 2017; 12(8):e0184065. PubMed ID: 28859139
    [TBL] [Abstract][Full Text] [Related]  

  • 48. The impact of laronidase treatment in otolaryngological manifestations of patients with mucopolysaccharidosis.
    Dualibi AP; Martins AM; Moreira GA; de Azevedo MF; Fujita RR; Pignatari SS
    Braz J Otorhinolaryngol; 2016; 82(5):522-8. PubMed ID: 26750310
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Laronidase-loaded liposomes reach the brain and other hard-to-treat organs after noninvasive nasal administration.
    Schuh RS; Franceschi EP; Brum BB; Fachel FNS; Poletto É; Vera LNP; Santos HS; Medeiros-Neves B; Monteagudo de Barros V; Helena da Rosa Paz A; Baldo G; Matte U; Giugliani R; Ferreira Teixeira H
    Int J Pharm; 2024 Jul; 660():124355. PubMed ID: 38897489
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Cognitive and neuroradiological improvement in three patients with attenuated MPS I treated by laronidase.
    Valayannopoulos V; Boddaert N; Barbier V; Le Merrer M; Caillaud C; de Lonlay P
    Mol Genet Metab; 2010 May; 100(1):20-3. PubMed ID: 20106688
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Cardiac findings after enzyme replacement therapy for mucopolysaccharidosis type I.
    Braunlin EA; Berry JM; Whitley CB
    Am J Cardiol; 2006 Aug; 98(3):416-8. PubMed ID: 16860035
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Combined enzyme replacement and haematopoietic stem cell transplantation in Hurler syndrome.
    Bijarnia S; Shaw P; Vimpani A; Smith R; Pacey V; O'Grady H; Christodoulou J; Sillence D
    J Paediatr Child Health; 2009; 45(7-8):469-72. PubMed ID: 19712183
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Limited data to evaluate real-world effectiveness of enzyme replacement therapy for mucopolysaccharidosis type I.
    Kuiper GA; Nijmeijer SCM; Roelofs MJM; van der Lee JH; Hollak CEM; Bosch AM
    J Inherit Metab Dis; 2019 Sep; 42(5):762-775. PubMed ID: 31020996
    [TBL] [Abstract][Full Text] [Related]  

  • 54. 12 year follow up of enzyme-replacement therapy in two siblings with attenuated mucopolysaccharidosis I: the important role of early treatment.
    Gabrielli O; Clarke LA; Ficcadenti A; Santoro L; Zampini L; Volpi N; Coppa GV
    BMC Med Genet; 2016 Mar; 17():19. PubMed ID: 26965916
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Early treatment with laronidase improves clinical outcomes in patients with attenuated MPS I: a retrospective case series analysis of nine sibships.
    Al-Sannaa NA; Bay L; Barbouth DS; Benhayoun Y; Goizet C; Guelbert N; Jones SA; Kyosen SO; Martins AM; Phornphutkul C; Reig C; Pleat R; Fallet S; Ivanovska Holder I
    Orphanet J Rare Dis; 2015 Oct; 10():131. PubMed ID: 26446585
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Agreement between the results of meta-analyses from case reports and from clinical studies regarding the efficacy of laronidase therapy in patients with mucopolysaccharidosis type I who initiated enzyme replacement therapy in adult age: An example of case reports meta-analyses as an useful tool for evidence-based medicine in rare diseases.
    Sampayo-Cordero M; Miguel-Huguet B; Pardo-Mateos A; Moltó-Abad M; Muñoz-Delgado C; Pérez-López J
    Mol Genet Metab; 2018 Feb; 123(2):69-75. PubMed ID: 29336994
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Successful pregnancy and breastfeeding in a woman with mucopolysaccharidosis type I while receiving laronidase enzyme replacement. therapy.
    Castorina M; Antuzzi D; Richards SM; Cox GF; Xue Y
    Clin Exp Obstet Gynecol; 2015; 42(1):108-13. PubMed ID: 25864295
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Mucopolysaccharidosis type I.
    Wraith JE; Jones S
    Pediatr Endocrinol Rev; 2014 Sep; 12 Suppl 1():102-6. PubMed ID: 25345091
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [The development of cognitive functions in children with Hurler phenotype mucopolysaccharidosis type I on enzyme replacement therapy with laronidase].
    Biernacka M; Jakubowska-Winecka A; Tylki-Szymańska A
    Pediatr Endocrinol Diabetes Metab; 2010; 16(4):249-54. PubMed ID: 21447265
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Laronidase for cardiopulmonary disease in Hurler syndrome 12 years after bone marrow transplantation.
    Valayannopoulos V; de Blic J; Mahlaoui N; Stos B; Jaubert F; Bonnet D; Fischer A; de Lonlay P
    Pediatrics; 2010 Nov; 126(5):e1242-7. PubMed ID: 20974778
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.